Territorial Availability: Available through Bertin Technologies only in France
Technical Warning: Bertin Technologies restricts the sale of this product to licensed controlled substance laboratories and qualified academic research institutions. Please contact us for further details.
Special Advice: Please check regulation status before ordering; additionel fees can apply.
- Synonyms
- 1-[(4-fluorophenyl)methyl]-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide
- Correlated keywords
- synthetics cannabinoids CBs cannabimimetic CB1 CB2 receptors agonists forensics AKB-48 JWH018 STS-135 analytical references standards AB-FUBINACA analogs peripheral central 4-fluorobenzyl AFB48 FUBAKB48 FUB-AKB-48 FUBAPINACA
- Product Overview:
AKB48 (Item No. ISO00060) is a pentyl indazole with structural similarity to the synthetic cannabinoids (CBs) JWH 018 adamantyl carboxamide (Item No. 9001193) and STS-135 (Item No. 11564), which have been sold for recreational use.{22837} Generally, quinolones with adamantyl-carboxamide moieties display high affinity for the peripheral cannabinoid (CB2) receptor but greatly reduced affinity for the central cannabinoid (CB1) receptor.{20020} AKB48 N-(4-fluorobenzyl) analog is an AKB48 derivative in which the pentyl chain has been replaced with a 4-fluorobenzyl group in order to mimic a structural feature of the potent CB1 modulator AB-FUBINACA (Item No. 14039). The physiological properties of this compound are not known. AKB48 N-(4-fluorobenzyl) analog is regulated as a Schedule I compound in the United States. This product is intended for research and forensic applications.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.